- Our Story
- In Memory
Awards and Recognition
Invitation to the White House
Cure Alzheimer’s Fund was one of a select few organizations invited to present information about the current state of Alzheimer’s research to key members of the current administration. Review of current research by Dr. Rudy Tanzi, chair of CAF’s Research Consortium, and presentation of recommendations for more and specifically focused federal funding for Alzheimer’s research by Tim Armour, president and CEO of CAF, and Jeff Morby, chairman and co-founder of CAF, were well received by senior members of the administration responsible for health and research policy.
Cure Alzheimer’s Fund achieves the Better Business Bureau “seal of approval” for meeting or exceeding the high standards set by BBB for well-run nonprofit organizations.
TIME/CNN recognizes the publication of an article in the American Journal of Human Genetics documenting a genome-wide association screen done by Cure Alzheimer’s Fund Research Consortium Chair Dr. Rudy Tanzi and his team. They collected genetic data from more than 1,300 families affected by Alzheimer’s disease, the largest such family-based screen ever conducted, to determine gene variants that influence one’s lifetime risk of Alzheimer’s. Out of 40 total genes identified from the screen, the American Journal of Human Genetics article highlighted four ‘novel’ genes that emerged as the top genetic connections to Alzheimer’s.
The MassGeneral Institute for Neurodegenerative Disease Award for Philanthropic Innovation and Investment presents the inaugural award for venture philanthropy in medical research to Cure Alzheimer’s Fund in recognition of CAF’s fast, focused, strategic funding of high-impact research.